Health ยท Pan-African
Unitaid Welcomes Royalty-Free Licences to Widen Access to Investigational Ebola Antiviral Obeldesivir
Unitaid has welcomed royalty-free voluntary licensing agreements between Gilead and three manufacturers for obeldesivir, an investigational antiviral being studied to prevent Bundibugyo Ebola disease. If trials support it and regulators approve it, the companies could supply it in 127 countries.
Unitaid has welcomed an announcement by Gilead of royalty-free voluntary licensing agreements for obeldesivir, an investigational antiviral that is being studied as a way to prevent Ebola Bundibugyo virus disease.
The licences have been granted to three manufacturers: Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories. Unitaid said the agreements lay the groundwork for wider access to the medicine.
Obeldesivir has not been approved for use against the disease. Unitaid said the arrangements would only take effect in practice if clinical evidence supports the medicine and regulators approve it. In that case, the three companies, which operate in different regions, would be able to produce and supply the antiviral in the 127 countries covered by the agreements.
The announcement shows access planning proceeding alongside the clinical studies, rather than waiting until their results are known. The medicine is still being evaluated, and no efficacy findings were supplied with the announcement.
The available information does not say which countries are among the 127, when the licences were signed, what trials are under way or where they are taking place. It also does not give a timeline for regulatory decisions or production.